In the News

Sep 10, 2010

Avastin’s commercial march suffers setback

Nature Biotechnology September 2010 - Vol 28 No 9

By Malorye Allison

Until July this year, when it slammed into a negative vote from a US Food and Drug Administration (FDA) advisory committee over its use in metastatic breast cancer, Avastin (bevacizumab) had been on an impressive roll. As the first drug specifically designed to block angiogenesis by inhibiting vascular endothelial growth factor (VEGF), it has accumulated several registered indications over only a few years.

Ed Kissel, Vice President, Quantitative Analysis at IntrinsiQ shares his views in the article.To read the full article, click here (subscription login required). For more information, contact